Drug Overview
Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) is an orally available small molecule inhibitor which has been shown to suppress tumor growth and metastasis by inhibiting the activity of multiple tyrosine kinases including MET, AXL, and vascular endothelial growth factor receptor (VEGFR). VEGF production is upregulated in renal cell carcinoma and results in increased tumor vascularization and disease progression. Standard first-line therapies such as Sutent (sunitinib; Pfizer) work by targeting VEGF/VEGFR signaling; however, tumors often develop resistance to these anti-angiogenic treatments.
Aberrant expression of MET and AXL tyrosine kinases is associated with drug resistance and poor disease prognosis; by targeting MET and AXL, as well as VEGF/VEGFR signaling, Cabometyx may provide an alternative treatment option for patients in the relapsed setting.
Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) is an orally available small molecule inhibitor which has been shown to suppress tumor growth and metastasis by inhibiting the activity of multiple tyrosine kinases including MET, AXL, and vascular endothelial growth factor receptor (VEGFR). VEGF production is upregulated in renal cell carcinoma and results in increased tumor vascularization and disease progression. Standard first-line therapies such as Sutent (sunitinib; Pfizer) work by targeting VEGF/VEGFR signaling; however, tumors often develop resistance to these anti-angiogenic treatments.
Aberrant expression of MET and AXL tyrosine kinases is associated with drug resistance and poor disease prognosis; by targeting MET and AXL, as well as VEGF/VEGFR signaling, Cabometyx may provide an alternative treatment option for patients in the relapsed setting.
Table of Contents
OVERVIEW- Drug Overview
- Product Profiles
- Cabometyx : Hepatocellular carcinoma (HCC)
- Cabometyx : Renal cell carcinoma (RCC)
LIST OF FIGURES
Figure 1: The author's drug assessment summary of Cabometyx for HCC
Figure 2: The author's drug assessment summary of Cabometyx for HCC
Figure 3: Cabometyx sales for HCC across the US, Japan, and five major EU markets, by country, 2018–27
Figure 4: Cabometyx for RCC – SWOT analysis
Figure 5: The author's drug assessment summary of Cabometyx for RCC
Figure 6: The author's drug assessment summary of Cabometyx for RCC
Figure 7: Cabometyx sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
Table 1: Recent high-impact events for Cabometyx in HCC
Table 2: Cabometyx drug profile
Table 3: Approval history of Cabometyx for HCC in the US, Japan, and five major EU markets
Table 4: Trials of Cabometyx for HCC
Table 5: Cabometyx for HCC – SWOT analysis
Table 6: Cabometyx drug profile
Table 7: Cabometyx Phase III data in RCC
Table 8: Cabometyx’s ongoing trials in RCC
Table 9: Cabometyx sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
